News: MMJ MMJ Phytotech receives approval to conduct MS phase 2 clinical trials, page-10

I think it's a convoluted situation, but my understanding is that MMJ Therapeutics owns the intellectual property behind the CBD capsule/Savitol. The Swiss company Gelpell manufactures the capsule based on its capsule formula while AiFame GmbH provides the compounds. Satipharm was the pharmaceutical division of MMJ (now owned by Harvest One), but the LOI's and IP are with MMJ. The PLT101 and the PTL201 trials are being undertaken by MMJ Therapeutics under the original clinical trial agreement. Satipharm own the capsule, but MMJ 'own' the trials.

According to the filing statement, " Satipharm and PhytoTech Therapeutics, a subsidiary of MMJ, have entered into an agreement: (i) that provides for PhytoTech Therapeutics to have continued access to cannabis products required to complete its proposed clinical trials and potentially thereafter commercially exploit any pharmaceutical products that result from the clinical trials; and (ii) restricting MMJ and PhytoTech Therapeutics from competing with the businesses of the Targets and any of their subsidiaries, all on terms acceptable to Harvest and MMJ, each acting reasonably".

Thus, by virtue of today's announcement and the filing statement, Satipharm must ensure CBD capsule supply to MMJ for clinical trials and distribution royalty free (no licensing fees) that are backed by trial results. Additionally, the results of the clinical trials using the Satipharm owned product can be exploited commercially by MMJ. Satipharm can't go stomping on MMJ's market either.....

Hope that makes some sense......it is bloody convoluted.....BTW, I think MMJ have finally updated their website, I'll have a look later to contrast it against their former site.